Balsalazide disodium for the treatment of ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 2, 2008, Pages 177-184

  Patil, Seema A ^a   Moss, Alan C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

4 ABA; Balsalazide; Balsalazide disodium; Balsalazine; BX661A; Colazal ; Colazide

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AMPICILLIN DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MEZAVANT; OLSALAZINE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ARTHRALGIA; BLOOD DYSCRASIA; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; COLON FLORA; COLORECTAL CANCER; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; ESOPHAGITIS; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; MALE INFERTILITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; NAUSEA; NONHUMAN; OLIGOSPERMIA; OTALGIA; PANCREATITIS; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PNEUMONIA; POSTMARKETING SURVEILLANCE; RECURRENCE RISK; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; TOXIC HEPATITIS; ULCERATIVE COLITIS; VOMITING;

COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; PHENYLHYDRAZINES;

EID: 55649099009     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.2.177     Document Type: Review

References (46)

1. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 34(1), 63-68 (2002).
2. Xavier RJ, Podolsky D. Unraveling the pathogenesis of inflammatory bowel disease. Nature 448(7152), 427-434 (2007).
3. Higgins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am. J. Gastroenterol. 100(2), 355-361 (2005).
4. Loftus EV. The burden of inflammatory bowel disease in the United States: a moving target? Clin. Gastroenterol. Hepatol. 5(12), 1383-1384 (2007).
5. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am. J. Gastroenterol. 99, 650-655 (2004).
6. Svartz N. Treatment of rheumatoid arthritis with salicylazosulfapyridine. Acta Med. Scand. 341(Suppl.), 247-254 (1958).
7. Baron JH, Connell AM, Lennard-Jones JE, and Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1, 1094-1096 (1962).
8. Azad Khan AK, Piris J, Trudove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2(8044), 892- 5 (1977).
9. Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 59(4), 939-956 (2000).
10. Chan RP, Pope DJ, Gilbert AP et al. Studies of two novel sulphasalazine analogs, ipsalazide and balsalazide. Dig. Dis. Sci. 28, 609-615 (1983).
11. Dubuquoy L et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55(9), 1341-1392 (2006).
12. Simmonds NJ, Millar AD, Blake DR et al. Antioxidant effects of aminosalicylates, and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 13(3), 363-372 (1999).
13. Peh K.H, Wan BC, Assem ES et al. Effect of Sulphasalazine and balsalazide on histamine release from mast cells. Inflamm. Res. 56(Suppl. 1), S9-S10 (2007).
14. Kles KA, Vavricka SR, Turner JR et al. Comparative analysis of the in vitro secretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm. Bowel Dis. 11(3), 253-257 (2005).
15. MacGregor DJ, Kim YS, Sleisenger MS et al. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6Min/+ mouse. Int J. Oncol. 17(1), 173-179 (2000).
16. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 17(1), 29-42 (2003).
17. Van Hees PA, Tuinte JH, van Rossum JM, van Tongeren JH. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 20, 300-304 (1979).
18. Houston JB, Day J, Walker J. Azo reduction of sulphasalazine in healthy volunteers. Br. J. Clin. Pharmacol. 14, 395-398 (1982).
19. Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). Clin. Pharmacokinet. 19(2), 94-125 (1990).
20. Lowry PW, Franklin CL, Weaver AL et al.. Leucopenia resulting from a drug interaction between azathioprine of 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49, 656-664 (2001).
21. Green JRB, Lobo AJ, Holdsworth CD et al.. Balsalazide is more effective and better tolerated than mesalamine in acute ulcerative colitis. Gastroenterology 115, 15-22 (1998).
22. Pruitt R, Hanson J, Safdi M et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild to moderate ulcerative colitis. Am. J. Gastroenterol. 97(12), 3078-3086 (2002).
23. Levine DS, Riff DS, Pruitt R et al. A randomized, double-blind dose-response comparison of balsalazide 6.75 g, balsalazide 2.25 g and mesalamine 2.4 g in the treatment of active, mild to moderate ulcerative colitis. Am. J. Gastroenterol. 97(6), 1398-1407 (2002).
24. Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am. J. Gastroenterol. 97(6), 1283-1285 (2002).
25. Mansfield JC, Giaffer MH, Cann PA et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 4 g, as sole therapy in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 16{1), 69-77 (2002).
26. Green JR, Mansfield JC, Gibson JA et al.. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment. Pharmacol. Ther. 16(1), 61-68 (2002).
27. Tursi A, Brandimarte G, Giorgetti GM et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit. 10(11), PI126-PI131 (2004).
28. McIntyre PB, Rodrigues CA, Lennard-Jones JE et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment. Pharmacol. Ther. 2, 237-243 (1988).
29. Kruis W, Schreiber S, Theuer D et al.. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 49, 783-789 (2001).
30. Giaffer MH, Holdsworth CD, Lennard-Jones JE et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment. Pharmacol. Ther. 6, 479-485 (1992).
31. Green JR, Swan CH, Rowlinson A et al.. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment. Pharmacol. Ther. 6, 647-652 (1992).
32. Green JR, Gibson JA, Kerr GD et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment. Pharmacol. Ther. 12(12), 1207-1216 (1998).
33. Moss AC, Peppercorn MA. The risks and benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin. Drug Saf. 6(2), 99-107 (2007).
34. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126, 1733 (2004).
35. Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment. Pharmacol. Ther. 17, 887-893 (2003).
36. Farrell RJ, Peppercorn MA, Fine SN, Michetti P. Mesalamine-associated thrombocytopenia. Am. J. Gastroenterol. 94, 2304-2306 (1999).
37. Adhiyaman V,, Vaishnavi A, Froese S. Hypersensitivity reaction to balsalazide. BMJ 320(7235), 613 (2000).
38. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100, 1345-1353 (2005).
39. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. PharmacoL. Ther. 14, 145-153 (2000).
40. Jahraus CD, Rubin DT, Scherl EJ et al. Inflammation's role in rectal cancer following prostate radiotherapy, and an emerging protective role for balsalazide. Gastroenterology 129(2), 770-772 (2005).
41. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 19(2), 179-189 (2004).
42. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to salphasalazine. Aliment. Pharmacol. Ther. 6, 51-59 (1992).
43. McIntyre PB, Lennard-Jones JE. Reversal with balsalazide of infertility caused by sulphasalazine. BMJ 288, 1652-1653 (1984).
44. Rutter M, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53(12), 1813-1816 (2004).
45. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18(2), 191-198 (2003).
46. Ediger JP, Walker JR, Graff L et al. Predictors of medication adherence in inflammatory bowel disease. Am. J. Gastroenterol. 102(7), 1417-1426 (2007).